Roche lung cancer treatment reports promising results in Phase III

pharmafile | March 22, 2021 | News story | Sales and Marketing Roche, oncology 

Roche’s IMpower010 study, evaluating Tecentriq (atezolizumab) compared with best supportive care, has shown significant improvement in disease-free survival (DFS) in the treatment of early stage, non-small cell lung cancer (NSCLC), it was announced today.

The Phase III study has become the first to show that a cancer immunotherapy improves DFS in people with resectable early stage lung cancer compared with best supportive care, with Tecentriq used as adjuvant therapy following surgery and chemotherapy.

Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development, said: “With these landmark results, Tecentriq has become the first cancer immunotherapy to help many people with resectable early lung cancer live longer without their cancer returning.

“We’re excited by the clinical benefit adjuvant Tecentriq may bring to lung cancer patients, particularly in the PD-L1-positive population. We will submit these data to regulatory authorities as soon as possible.”

Follow-up will continue with planned analysis of DFS in the overall intent-to-treat population, which at the time of analysis did not cross the threshold, and overall survival data, which were immature at the time of interim analysis.

Roche will present results from the Impower010 study at an upcoming medical meeting and it will subsequently be submitted to global health authorities, including the FDA and EMA.

Tecentriq has previously shown benefits in various types of lung cancer, with five currently approved indications in markets around the world. It was also the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer (SCLC) in combination with carboplatin and etoposide.

Roche has an extensive development programme for Tecentriq, including multiple ongoing and planned Phase III studies across different lung, genitourinary, skin, breast, gastrointestinal, gynaecological, and head and neck cancers. This includes studies evaluating Tecentriq both alone and in combination with other medicines, as well as studies in metastatic, adjuvant, and neoadjuvant settings across various tumour types.

Kat Jenkins


Related Content


BioInvent and Transgene announce positive phase 1a solid tumour trial data

Sweden-based BioInvent and French Transgene, both biotech companies, have reported positive phase 1a data from …


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

FDA announces acceptance and priority review of NDA for LUMISIGHT imagining agent for breast cancer

Lumicell has announced that the US Food and Drug Administration (FDA) has accepted and granted …

Latest content